Zenocutuzumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Zenocutuzumab
Accession Number
DB15559
Type
Biotech
Groups
Investigational
Description

Zenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).

Synonyms
  • Immunoglobulin g1, bispecific, anti-(human epidermal growth factor receptors, her2 and her3) (humanized clone mcla-128 .gamma.1-chain), disulfide with humanized clone mcla-128 light chain, dimer
  • Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
  • Zenocutuzumab
External IDs
MCLA-128
Categories
UNII
AE72RB1W1X
CAS number
1969309-56-5

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Zenocutuzumab.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Zenocutuzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Abrilumab is combined with Zenocutuzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Zenocutuzumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Zenocutuzumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Zenocutuzumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Zenocutuzumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zenocutuzumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Zenocutuzumab.
AmatuximabThe risk or severity of adverse effects can be increased when Amatuximab is combined with Zenocutuzumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingTreatmentBreast Cancer / Colorectal Cancers / Endometrial Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Stomach / Malignant Solid Tumours / NRG1 Fusion / NSCLC Harboring NRG1 Fusion / Ovarian Cancer / Pancreatic Cancer Harboring NRG1 Fusion / Solid Tumours Harboring NRG1 Fusion1
2RecruitingTreatmentMetastatic Breast Cancer1
Not AvailableAvailableNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / NRG1 / NRG1 Fusion / Solid Tumor, Unspecified, Adult1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on October 17, 2019 09:15 / Updated on November 02, 2019 03:34